SEC Company Response from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Feb 6, 2019
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 6, 2019 · CIK: 0001671502 · Accession: 0001213900-19-001763
AI Filing Summary & Sentiment
File numbers found in text: 333-229083
Show Raw Text
CORRESP
1
filename1.htm
February 6, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Cellect Biotechnology Ltd. (CIK: 0001671502)
Registration Statement No. 333-229083
on Form F-1 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules
and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities
Act”), Alliance Global Partners, as representative of the underwriters, hereby requests acceleration of the effective date
of the above-referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, February 7, 2019, or
as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act,
please be advised that we, acting on behalf of the several underwriters, will distribute as many electronic copies of the proposed
form of preliminary prospectus as appears to be reasonable to secure adequate distribution.
By:
ALLIANCE GLOBAL PARTNERS
By:
/s/
Thomas Higgins
Name: Thomas Higgins
Title: Managing
Director, Investment Banking